Trulieve Cannabis (NYSE:TRLV) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Trulieve Cannabis (NYSE:TRLV) in a research report report published on Monday, Marketbeat reports. The brokerage issued an overweight rating and a $15.00 target price on the stock.

Several other brokerages also recently issued reports on TRLV. Weiss Ratings assumed coverage on Trulieve Cannabis in a research report on Tuesday, June 16th. They set a “sell (d-)” rating for the company. Zacks Research raised Trulieve Cannabis to a “hold” rating in a report on Thursday, June 18th. Finally, Wall Street Zen cut Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Trulieve Cannabis presently has a consensus rating of “Hold” and an average target price of $15.00.

Trulieve Cannabis Stock Performance

NYSE TRLV opened at $8.73 on Monday. Trulieve Cannabis has a 52 week low of $4.00 and a 52 week high of $13.28.

Insider Transactions at Trulieve Cannabis

In related news, CEO Kim A. Rivers sold 400,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.17, for a total value of $3,268,000.00. Following the completion of the transaction, the chief executive officer owned 1,913,724 shares in the company, valued at $15,635,125.08. This represents a 17.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,699,007 shares of company stock valued at $14,661,355. Corporate insiders own 3.79% of the company’s stock.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.